PERTOFRANE
LOE ApproachingNDAORALCAPSULE
Approved
Apr 1968
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed Yesterday · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PERTOFRANE is an oral small-molecule capsule approved in 1968 by Sanofi as an NDA product. The generic composition and mechanism of action are not currently documented in available data. Patient indications and therapeutic class require clarification from current product labeling.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30/100); team size and budget allocation likely contracting.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings indicate minimal active hiring for PERTOFRANE positions. Working on this legacy product offers stability but limited advancement; career value lies in operational management and cost containment expertise rather than growth or innovation.
Brand ManagerProduct Manager
Worked on PERTOFRANE at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.